Cargando…

The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis

BACKGROUND: A combination of temozolomide (TMZ) and radiotherapy and subsequent adjuvant chemotherapy is the gold standard of treatment for glioblastoma (GB). Bevacizumab (BEV), a humanized monoclonal antibody that blocks the effects of vascular endothelial growth factor A, has produced impressive r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Ke-Li, Huang, Song, Wu, Yu-Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016281/ https://www.ncbi.nlm.nih.gov/pubmed/29950856 http://dx.doi.org/10.2147/OTT.S156723

Ejemplares similares

In silico analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma
por: Hawkins-Daarud, Andrea, et al.
Publicado: (2015)

Timing of bevacizumab administration after biopsy for unresectable newly diagnosed glioblastoma
por: Matsuda, Masahide, et al.
Publicado: (2022)

The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients
por: Poulsen, Hans Skovgaard, et al.
Publicado: (2014)

The Prognosis of Anti-Angiogenesis Treatments Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled Trials
por: Li, Yuping, et al.
Publicado: (2016)

Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis
por: Li, Xiaoqing, et al.
Publicado: (2015)

Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis
por: Kaka, Nagham, et al.
Publicado: (2019)

Interstitial photodynamic therapy for newly diagnosed glioblastoma
por: Quach, Stefanie, et al.
Publicado: (2023)

Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study
por: Nagane, Motoo, et al.
Publicado: (2022)

Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab
por: Wen, Qiuting, et al.
Publicado: (2014)

Prognosis of patients with newly diagnosed glioblastoma treated with molecularly targeted drugs combined with radiotherapy vs temozolomide monotherapy: A meta-analysis
por: Wang, Wen-Lei, et al.
Publicado: (2019)

Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials
por: Du, Chigang, et al.
Publicado: (2016)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

Effectiveness of Lomustine Combined With Bevacizumab in Glioblastoma: A Meta-Analysis
por: Ren, Xing, et al.
Publicado: (2021)

Effect of Cadherin-11 Expression on the Prognosis of a Newly Diagnosed Primary Glioblastoma
por: Seo, Hyunwoo, et al.
Publicado: (2021)

The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial
por: Weller, Johannes, et al.
Publicado: (2023)

Advances in the treatment of newly diagnosed glioblastoma
por: Theeler, Brett J., et al.
Publicado: (2015)

A Review of Newly Diagnosed Glioblastoma
por: Oronsky, Bryan, et al.
Publicado: (2021)

Newly Diagnosed Glioblastoma in Elderly Patients
por: Yuen, Carlen A., et al.
Publicado: (2022)

Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme
por: Aherne, Noel J., et al.
Publicado: (2014)

Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis
por: Song, Jie, et al.
Publicado: (2018)

Magnetic Resonance Imaging-Based Radiomic Profiles Predict Patient Prognosis in Newly Diagnosed Glioblastoma Before Therapy
por: McGarry, Sean D., et al.
Publicado: (2016)

Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial
por: Boisen, Mogens K., et al.
Publicado: (2017)

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)
por: Reyes‐Botero, Germán, et al.
Publicado: (2018)

Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab
por: Nelson, Sarah J., et al.
Publicado: (2016)

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
por: Omar, Ayman I.
Publicado: (2014)

Role of bevacizumab therapy in the management of glioblastoma
por: Peak, Scott J, et al.
Publicado: (2010)

Correction: Newly Diagnosed Glioblastoma in Elderly Patients
por: Yuen, Carlen A., et al.
Publicado: (2022)

Bevacizumab combined with re-irradiation in recurrent glioblastoma
por: She, Lei, et al.
Publicado: (2022)

Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis
por: Suh, Young Ju, et al.
Publicado: (2022)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials
por: Yang, Shou-Bo, et al.
Publicado: (2017)

A comparison between oral chemotherapy combined with radiotherapy and radiotherapy for newly diagnosed glioblastoma: A systematic review and meta-analysis
por: Wang, Zhuo, et al.
Publicado: (2017)

Impact of Neoadjuvant Bevacizumab on Neuroradiographic Response and Histological Findings Related to Tumor Stemness and the Hypoxic Tumor Microenvironment in Glioblastoma: Paired Comparison Between Newly Diagnosed and Recurrent Glioblastomas
por: Takei, Jun, et al.
Publicado: (2022)

Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies
por: Singleton, Kyle W, et al.
Publicado: (2020)

Comparison of peripheral leukocyte parameters in patients receiving conventionally and hypofractionated radiotherapy schemes for the treatment of newly diagnosed glioblastoma
por: Greenlund, Lindsey, et al.
Publicado: (2023)

Efficacy and Safety of Hypofractionated Radiotherapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme: A Systematic Review and Meta-Analysis
por: Liao, Guixiang, et al.
Publicado: (2019)

ACT-26 PATTERN OF RECURRENCE IN NEWLY DIAGNOSED GLIOBLASTOMA TREATED WITH PHOTODYNAMIC THERAPY
por: Nakayama, Noriyuki, et al.
Publicado: (2022)

COT-20 Clinical experience with tumor-treating fields therapy for newly diagnosed glioblastoma
por: Saito, Norihiko, et al.
Publicado: (2020)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

Subclassification of Newly Diagnosed Glioblastomas through an Immunohistochemical Approach
por: Conroy, Siobhan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_s8qkona3rv86nifbmm01r6uqar